- 180 Life Sciences ( NASDAQ: ATNF ) is up 12% in Wednesday morning trading following the publication of a review on treatment for Dupuytren's disease that identified tumor necrosis factor as a potential target.
- The review also included results from a phase 2a dose ranging trial that identified the most efficacious dose and formulation of AbbVie's ( ABBV ) Humira (adalimumab), an anti-TNF therapy. A phase 2b trial met the primary endpoint of reduction in nodule hardness and a secondary endpoint of decrease in nodule size.
- The company said there are no treatment options for early-stage disease. For advanced disease, surgery, needle aponeurotomy or collagenase injections are options, though they come with a high rate of recurrence.
- Seeking Alpha's Quant Rating views 180 Life Sciences ( ATNF ) as a strong sell.
For further details see:
180 Life Sciences up 12% on tumor necrosis factor as target for Dupuytren’s disease